DICE Therapeutics Announces Pricing of Upsized Initial Public Offering

September 17, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by DICE. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204.0 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.”